STOCKSCREENR

RIGL

NASDAQ

Rigel Pharmaceuticals, Inc.

$29.40+0.50(+1.73%)Mkt Cap: $543.31M

Key Stats

Market Cap

$543.31M

P/E Ratio

1.51

EPS

$19.48

Dividend Yield

0.00%

52-Week Range

$16.88 — $52.24

Volume

177.72K

Avg Volume

348.90K

Beta

1.27

Price Alerts for RIGL

Get alerted when RIGL hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

1.51

Forward P/E

6.77

PEG Ratio

0.01

P/S (TTM)

1.72

P/B (TTM)

1.26

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

2.41%

ROA (TTM)

0.71%

ROIC

—

Gross Margin

0.93%

Operating Margin

0.43%

Net Margin

—

Debt/Equity

0.14

Current Ratio

2.42

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.06%

EPS Growth (5Y)

+0.22%

Sales Growth (3Y)

+0.10%

Sales Growth (5Y)

+0.30%

EPS Est (This Year)

$4.35

EPS Est (Next Year)

$4.17

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$8.61

Analyst Consensus

Price Target Range

$38.00$40.00$42.00
LowMedianHigh

Consensus Target: $40.00(36.1% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

18.47M

Float

18.18M

Free Float %

98.40%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2000-11-29

Employees

162

CEO

Raul R. Rodriguez

Index Membership

—

Website

https://www.rigel.com

Rigel Pharmaceuticals, Inc. (RIGL) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $543.31M, a P/E ratio of 1.51, RIGL is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare RIGL against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

ARMP

Armata Pharmaceuticals, Inc.

$8.89

-10.92%

$325.67M

CBIO

Crescent Biopharma, Inc.

$18.07

-19.22%

$498.22M

ZBIO

Zenas BioPharma, Inc.

$19.36

+0.21%

$864.29M

GHRS

GH Research PLC

$20.71

+0.88%

$1.28B

BHVN

Biohaven Ltd.

$9.63

+0.42%

$1.02B

Frequently Asked Questions

What is Rigel Pharmaceuticals, Inc.'s P/E ratio?

Rigel Pharmaceuticals, Inc. (RIGL) has a trailing twelve-month (TTM) P/E ratio of 1.51. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Rigel Pharmaceuticals, Inc. pay a dividend?

No, Rigel Pharmaceuticals, Inc. (RIGL) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Rigel Pharmaceuticals, Inc.'s market cap?

Rigel Pharmaceuticals, Inc. (RIGL) has a market capitalization of $543.31 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.